Stryker Corporation $SYK Stock Sold by Bank Pictet & Cie Europe AG

Bank Pictet & Cie Europe AG decreased its stake in shares of Stryker Corporation (NYSE:SYK) by 6.1% during the third quarter, Holdings Channel reports. The firm owned 137,401 shares of the medical technology company’s stock after selling 8,958 shares during the quarter. Bank Pictet & Cie Europe AG’s holdings in Stryker were worth $37,839,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in SYK. Mitchell Mcleod Pugh & Williams Inc. grew its position in Stryker by 1.2% in the 1st quarter. Mitchell Mcleod Pugh & Williams Inc. now owns 2,678 shares of the medical technology company’s stock worth $880,000 after purchasing an additional 31 shares during the period. Community Bank & Trust Waco Texas lifted its holdings in shares of Stryker by 2.3% during the 2nd quarter. Community Bank & Trust Waco Texas now owns 1,395 shares of the medical technology company’s stock valued at $439,000 after buying an additional 31 shares during the period. Cornerstone Financial Management LLC lifted its holdings in shares of Stryker by 66.0% during the 2nd quarter. Cornerstone Financial Management LLC now owns 78 shares of the medical technology company’s stock valued at $25,000 after buying an additional 31 shares during the period. NWF Advisory Services Inc. lifted its holdings in shares of Stryker by 2.3% during the 2nd quarter. NWF Advisory Services Inc. now owns 1,472 shares of the medical technology company’s stock valued at $463,000 after buying an additional 33 shares during the period. Finally, Harold Davidson & Associates Inc. boosted its stake in shares of Stryker by 0.4% in the 1st quarter. Harold Davidson & Associates Inc. now owns 8,668 shares of the medical technology company’s stock worth $2,848,000 after buying an additional 34 shares during the last quarter. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Stryker Stock Performance

Shares of NYSE:SYK traded up $5.92 during midday trading on Tuesday, hitting $303.86. The company had a trading volume of 1,026,447 shares, compared to its average volume of 2,445,313. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The company has a market cap of $116.55 billion, a price-to-earnings ratio of 31.50, a PEG ratio of 1.87 and a beta of 0.78. Stryker Corporation has a 12-month low of $267.00 and a 12-month high of $392.55. The company has a fifty day moving average of $298.39 and a two-hundred day moving average of $312.55.

Stryker (NYSE:SYK) last announced its earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analysts’ expectations of $6.58 billion. Stryker had a return on equity of 23.63% and a net margin of 14.43%. Stryker’s revenue for the quarter was up 9.4% compared to the same quarter last year. During the same period last year, the firm earned $3.13 EPS. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. On average, equities research analysts expect that Stryker Corporation will post 14.93 EPS for the current fiscal year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be given a $0.88 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $3.52 dividend on an annualized basis and a yield of 1.2%. Stryker’s dividend payout ratio is presently 36.48%.

Insider Transactions at Stryker

In other news, insider Dylan Crotty sold 441 shares of the firm’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $328.61, for a total value of $144,917.01. Following the transaction, the insider owned 6,102 shares of the company’s stock, valued at $2,005,178.22. This trade represents a 6.74% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Debra King sold 826 shares of Stryker stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total value of $277,783.80. Following the transaction, the insider directly owned 6,210 shares in the company, valued at approximately $2,088,423. The trade was a 11.74% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 351,267 shares of company stock valued at $118,197,701 over the last quarter. 4.60% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

SYK has been the subject of several research analyst reports. Evercore set a $350.00 price objective on Stryker in a report on Monday, July 6th. Sanford C. Bernstein reissued a “market perform” rating on shares of Stryker in a report on Wednesday, October 7th. Stifel Nicolaus lowered their target price on Stryker from $360.00 to $330.00 and set a “buy” rating on the stock in a report on Wednesday, September 30th. TD Cowen dropped their target price on Stryker from $355.00 to $298.00 and set a “hold” rating on the stock in a research report on Tuesday, September 22nd. Finally, Canaccord Genuity Group cut their price target on Stryker from $400.00 to $385.00 and set a “buy” rating for the company in a research note on Friday, September 18th. One analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $369.00.

Stryker Company Profile

Stryker Corporation (NYSE: SYK) is a global medical technology company that develops and manufactures products used by healthcare providers in hospitals, surgical centers and other clinical settings. Its offerings are designed to support orthopaedic procedures, surgery, emergency care, neurovascular treatment and patient handling.

The company’s product portfolio includes orthopaedic implants and instruments, products for trauma and spine procedures, surgical equipment, endoscopy systems, patient beds and stretchers, emergency medical equipment, and neurovascular devices used in the treatment of conditions such as stroke.